Selzentry approval marks big win for Pfizer

Pfizer won accelerated approval from the FDA for Selzentry, the first HIV therapy in a new class of drugs in a decade. The drug (maraviroc) is a CCR5 antagonist, which prevents the virus from entering white blood cells. The process reduces viral load and boosts T-cell count. In the next step of regulatory review, Pfizer will provide additional data to gain a traditional approval of the drug. The approval is notable for a variety of reasons. For Pfizer, it's a much-needed win on the regulatory side after a series of disappointing setbacks in its pipeline development program. For the FDA, the accelerated approval may help tone down some growing complaints that the agency has grown shy about swift approvals in light of a number of safety problems with therapeutics.

- see the release on the approval
- here's the Forbes report

ALSO: Pfizer has updated its public R&D pipeline site for the first time since it went online in December. FiercePharma

Related Articles:
Investors yawn at Maraviroc endorsement. Report
New HIV drugs offer breakthrough therapies. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.